SGX-523
目录号:S1112 Purity: 99.78%
SGX-523是一种选择性的Met (c-Met)抑制剂,IC50为4 nM,对BRAFV599E, c-Raf, Abl和p38α无抑制活性。Phase 1。
CAS: 1022150-57-7
客户使用Selleck的SGX-523发表文献133篇
- Nature, 2022 605(7910):539-544
- Cancer Cell, 2022 S1535-6108(22)00312-9
- Cell Discov, 2022 8(1):74
- Nat Metab, 2022 4(6):759-774
- Blood, 2022 blood.2021014304
- Am J Respir Crit Care Med, 2016 10.1164/rccm.201509-1878OC
- J Hepatol, 2014 60(1):143-51
- PLoS Pathog, 2023 19(8):e1011579
- Pharmacol Res Perspect, 2023 11(1):e01047
- bioRxiv, 2023 2023.02.23.529756
- Nat Commun, 2022 13(1):4757
- Adv Sci (Weinh), 2022 9(21):e2201258
- Adv Sci (Weinh), 2022 9(17):e2105316
- Nucleic Acids Res, 2022 gkac676
- Biomaterials, 2022 285:121549
- Biosens Bioelectron, 2022 212:114405
- Dev Cell, 2022 57(7):901-913.e4
- EMBO J, 2022 41(16):e110636
- Proc Natl Acad Sci U S A, 2022 119(26):e2201490119
- Research (Wash D C), 2022 2022:9814652
- Environ Sci Technol, 2022 56(9):5694-5705
- Environ Sci Technol, 2022 56(4):2312-2322
- J Nanobiotechnology, 2022 20(1):278
- Sci Total Environ, 2022 824:153870
- Metabolism, 2022 134:155266
- ACS Appl Mater Interfaces, 2022 14(24):27651-27665
- Pharmacol Res, 2022 182:106324
- Int J Biol Sci, 2022 18(3):911-922
- Cell Death Dis, 2022 13(8):711
- Chemosphere, 2022 300:134617
- Cell Rep, 2022 38(9):110455
- Int J Biol Macromol, 2022 207:905-916
- Acta Pharmacol Sin, 2022 43(10):2585-2595
- Mol Metab, 2022 S2212-8778(22)00153-3
- EMBO Rep, 2022 6;23(10):e54543.
- Stem Cell Res Ther, 2022 13(1):59
- Oxid Med Cell Longev, 2022 2022:7420507
- Oxid Med Cell Longev, 2022 2022:8645830
- Front Immunol, 2022 13:877815
- Phytother Res, 2022 36(6):2558-2571
- Cell Death Discov, 2022 8(1):89
- Ecotoxicol Environ Saf, 2022 233:113319
- Biomater Sci, 2022 10(11):2857-2864
- Eur J Cell Biol, 2022 101(4):151272
- J Lipid Res, 2022 63(9):100261
- mBio, 2022 e0200422.
- Neural Regen Res, 2022 17(12):2778-2784
- Food Funct, 2022 13(16):8662-8675
- Food Funct, 2022 13(11):6166-6179
- J Agric Food Chem, 2022 70(14):4353-4361
- J Agric Food Chem, 2022 70(34):10532-10542
- Nutrients, 2022 14(8)1620
- Front Bioeng Biotechnol, 2022 10:872088
- Front Plant Sci, 2022 13:912215
- Front Pharmacol, 2022 13:823266
- Front Plant Sci, 2022 13:906603
- Int J Mol Sci, 2022 23(11)6260
- J Nutr Biochem, 2022 S0955-2863(22)00201-7
- Biomolecules, 2022 12(3)388
- Am J Cancer Res, 2022 12(1):327-336
- J Cell Mol Med, 2022 26(10):2947-2958
- Cancers (Basel), 2022 14(13)3110
- Plant Sci, 2022 319:111260
- Front Microbiol, 2022 13:851706
- Virus Res, 2022 318:198851
- Mol Ecol, 2022 31(9):2611-2624
- FASEB J, 2022 36(7):e22410
- Front Oncol, 2022 12:809760
- Fish Shellfish Immunol, 2022 S1050-4648(22)00534-4
- Sci Rep, 2022 12(1):9033
- Development, 2022 149(10)dev200321
- J Oncol, 2022 2022:9514697
- J Proteome Res, 2022 21(2):313-324
- Neurochem Res, 2022 47(7):2002-2015
- Cell Cycle, 2022 1-15
- J Diabetes Res, 2022 2022:8938276
- Pest Manag Sci, 2022 78(11):4628-4637
- J Immunol Res, 2022 2022:8307280
- J Appl Microbiol, 2022 133(2):707-719
- Front Med (Lausanne), 2022 9:892593
- Plant Biol (Stuttg), 2022 24(3):510-516
- Oral Dis, 2022 10.1111/odi.14223
- Cell Stress Chaperones, 2022 10.1007/s12192-022-01265-1
- Virology, 2022 574:25-36
- Exp Cell Res, 2022 417(1):113196
- Toxicol Lett, 2022 367:40-47
- Gene, 2022 823:146327
- Cancer Biother Radiopharm, 2022 10.1089/cbr.2021.0344
- Fitoterapia, 2022 158:105165
- Immunopharmacol Immunotoxicol, 2022 44(1):7-16
- Parasit Vectors, 2022 15(1):177
- Life (Basel), 2022 12(8)1147
- Mol Genet Genomics, 2022 10.1007/s00438-022-01936-9
- BMC Pulm Med, 2022 22(1):321
- Brain Res, 2022 1780:147802
- Evid Based Complement Alternat Med, 2022 2022:4675815
- Beilstein J Org Chem, 2022 18:916-925
- J Anim Physiol Anim Nutr (Berl), 2022 10.1111/jpn.13698
- BMC Vet Res, 2022 18(1):311
- Tissue Cell, 2022 76:101749
- BMC Vet Res, 2022 18(1):179
- J Comp Neurol, 2022 30(17):3056-3071
- Int J Gen Med, 2022 15:1497-1508
- Sci Adv, 2022 8(15):eabm4646
- Int J Clin Exp Pathol, 2022 15(5):206-214
- ACS Pharmacol Transl Sci, 2022 5(7):479-490
- Nan Fang Yi Ke Da Xue Xue Bao, 2022 42(6):840-848
- Nan Fang Yi Ke Da Xue Xue Bao, 2022 42(2):250-255
- Front Bioeng Biotechnol, 2021 9:733582
- Front Cell Dev Biol, 2021 9:817779
- Front Endocrinol (Lausanne), 2021 12:778019
- Acta Pharmacol Sin, 2020 10.1038/s41401-019-0336-3
- J Pathol, 2020 250(2):205-216
- Neurooncol Adv, 2020 2(1):vdaa067
- Nat Commun, 2019 10(1):2701
- Cell Rep, 2019 28(9):2331-2344
- Sci Rep, 2019 9(1):1897
- Sci Rep, 2019 9(1):1988
- Cancer Res, 2018 78(15):4360-4369
- Sci Rep, 2018 8(1):11894
- Sci Rep, 2018 8(1):1955
- Nat Commun, 2016 7:10690
- Cancer Res, 2016 76(6):1506-16
- Acta Pharmacol Sin, 2016 37(12):1587-1596
- Int J Oncol, 2015 47(1):71-80
- Oncoscience, 2015 2(4):419-427
- Clin Cancer Res, 2013 19(9):2584-91
- Clinical Cancer Research, 2013 19(9)
- Biomarkers, 2013 18(2):126-35
- Neuro Oncol, 2012 15(2):161-71
- Proc Natl Acad Sci USA, 2012 109(31):E2127-33
- Mol Cell Proteomics, 2012 11(6):M112.017764
- Neoplasia, 2011 13(12):1132-42
化学信息&溶解度
分子量 | 359.41 |
分子式 | C18H13N7S |
CAS号 | 1022150-57-7 |
Smiles | CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 2 mg/mL ( 5.56 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 2 mg/mL ( 5.56 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 3 mg/mL ( 8.34 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
0.5% methylcellulose
0.2% Tween 80
浓度:10mg/ml
(27.82mM)
操作示例:以1 mL工作液为例,取10 mg此产品,加入到1ml的0.5% methylcellulose+0.2% Tween 80澄清溶液,混合均匀使其成为均匀悬浊液。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。